ArticleSchizophrenia (Heidelberg, Germany)2025
Alterations in serum IL-10 and IL-19 levels in drug-naïve first-episode adolescent-onset schizophrenia and their associations with clinical symptoms.
Article in Schizophrenia (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The impact of functional architecture dynamics in bipolar disorder staging.NeuroImage. Clinical · 2026Article
- Decreased serum IGFBP-7 level is associated with cognitive impairment in first-episode drug-naïve adolescent-onset schizophrenia.Annals of general psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-inflammatory mechanisms in schizophrenia have received widespread attention, but the levels of interleukin-10 (IL-10) and interleukin-19 (IL-19) and their associations with clinical symptoms in adolescent-onset schizophrenia (AOS) remain unclear. This study aimed to investigate serum IL-10 and IL-19 levels in AOS patients and their relationships with clinical symptoms. This cross-sectional study enrolled 83 drug-naïve first-episode AOS patients and 40 healthy controls. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS). Compared with healthy controls, AOS patients exhibited significantly decreased serum IL-10 levels (P = 0.007), elevated IL-19 levels (P = 0.014), and an increased IL-19/IL-10 (P < 0.001). Serum IL-10 levels in AOS patients were significantly negatively correlated with PANSS negative factor scores (r = -0.254, P = 0.020) and excitement/hostility factor scores (r = -0.348, P = 0.001), while the IL-19/IL-10 was positively correlated with excitement/hostility factor scores (r = 0.349, P = 0.001). Exploratory stratified analyses revealed significant negative correlations between IL-10 and excitement/hostility factor in both male patients (r = -0.432, P = 0.010) and female patients (r = -0.375, P = 0.009). Additionally, lower IL-10 levels were an independent predictor of AOS (RR = 0.808, 95%CI: 0.714-0.914, P = 0.001). AOS patients demonstrated an immune imbalance characterized by decreased serum IL-10, elevated IL-19 levels, and an increased IL-19/IL-10. IL-10 levels and the IL-19/IL-10 were closely associated with negative and excitement/hostility symptoms in AOS, with this association exhibiting sex differences. These findings suggest that IL-10 and the pro-inflammatory/anti-inflammatory balance may play an important role in the pathophysiological mechanism of AOS.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.